

Title (en)
SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D₃ RECEPTORS

Title (de)
SUBSTITUIERTE TETRAHYDROISOCHINOLINEDERIVATE ALS DOPAMINE D₃ REZEPTOR-MODULATOREN

Title (fr)
DERIVES DE TETRAHYDRO-ISOQUINOLINE SUBSTITUEE, UTILES EN TANT QUE MODULATEURS DES RECEPTEURS D₃ DE LA DOPAMINE

Publication
EP 0981516 A1 20000301 (EN)

Application
EP 98929278 A 19980427

Priority
• EP 9802581 W 19980427
• GB 9708694 A 19970430

Abstract (en)
[origin: WO9849145A1] Compounds of formula (I), wherein R₁ represents a substituent selected from a hydrogen or halogen atom; a hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethanesulfonyloxy, pentafluoroethyl, C₁-4alkyl, C₁-4alkoxy, arylC₁-4alkoxy, C₁-4alkylthio, C₁-4alkoxyC₁-4alkyl, C₃-6cycloalkylC₁-4alkoxy, C₁-4alkanoyl, C₁-4alkoxycarbonyl, C₁-4alkylsulphonyl, C₁-4alkylsulphonyloxy, C₁-4alkylsulphonylC₁-4alkyl, arylsulphonyl, arylsulphonyloxy, arylsulphonylC₁-4alkyl, C₁-4alkylsulphonamido, C₁-4alkylamido, C₁-4alkylsulphonamidoC₁-4alkyl, C₁-4alkylamidoC₁-4alkyl, arylsulphonamido, arylcarboxamido, arylsulphonamidoC₁-4alkyl, arylcarboxamidoC₁-4alkyl, aroyl, aroylC₁-4alkyl, or arylC₁-4alkanoyl group; a group R₃OCO(CH₂)_p, R₃CON(R₄)(CH₂)_p, R₃R₄NCO(CH₂)_p or R₃R₄NSO₂(CH₂)_p where each of R₃ and R₄ independently represents a hydrogen atom or a C₁-4alkyl group or R₃R₄ forms part of a C₃-6 azacycloalkane or C₃-6(2-oxo)azacycloalkane ring and p represents zero or an integer from 1 to 4; or a group Ar₁Z, wherein Ar₁ represents an optionally substituted phenyl ring or an optionally substituted 5- or 6-membered aromatic heterocyclic ring and z represents a bond, O, S, or CH₂; R₂ represents a hydrogen atom or a C₁-4alkyl group; q is 1 or 2; Ar represents an optionally substituted phenyl ring or an optionally substituted 5- or 6-membered aromatic heterocyclic ring; or an optionally substituted bicyclic ring system; and salts thereof. Compounds of formula (I) and their salts have affinity for dopamine receptors, in particular the D₃ receptor, and thus potential in the treatment of conditions wherein modulation of the D₃ receptor is beneficial, e.g. as antipsychotic agents.

IPC 1-7
C07D 217/04; **C07D 401/12**; **C07D 409/12**; **A61K 31/47**

IPC 8 full level
A61K 31/4725 (2006.01); **A61P 25/18** (2006.01); **A61P 43/00** (2006.01); **C07D 217/04** (2006.01); **C07D 401/12** (2006.01); **C07D 409/12** (2006.01)

CPC (source: EP)
A61P 25/18 (2017.12); **A61P 43/00** (2017.12); **C07D 217/04** (2013.01); **C07D 401/12** (2013.01); **C07D 409/12** (2013.01)

Citation (search report)
See references of WO 9849145A1

Cited by
US10870660B2; US11345716B2; US11897899B2

Designated contracting state (EPC)
BE CH DE ES FR GB IT LI NL

DOCDB simple family (publication)
WO 9849145 A1 19981105; CA 2288308 A1 19981105; EP 0981516 A1 20000301; GB 9708694 D0 19970618; JP 2001522366 A 20011113

DOCDB simple family (application)
EP 9802581 W 19980427; CA 2288308 A 19980427; EP 98929278 A 19980427; GB 9708694 A 19970430; JP 54662098 A 19980427